All News
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
Unilever announced Wednesday that it will not increase its bid over the recently proposed £50 billion (about $68 billion) to ensure that the acquisitions create value for its shareholders.
With more and more people applying for remote positions, how can you stand out among the massive stacks of applications?
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
Rising adoption of disposable filters, increasing use of single-use technologies, and rapid development of wastewater purification plants are key factors driving market growth.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The company plans to use the money to boost its drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.
AstraZeneca has been struggling to find an effective use for its anti-CTLA-4 antibody tremelimumab. It may have finally found it.
A checkpoint inhibitor under development from China’s CStone Pharmaceuticals hit the mark in a Phase III non-small cell lung cancer study.
A study conducted by 23andMe and published in Nature Genetics identified a genetic risk factor tied to the loss of smell from COVID-19.
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
The FDA issued the partial clinical hold order in response to the IND application Yumanity submitted in December last year. The company expects additional data on the directive within the next 30 days.
UCB has announced that it is acquiring Zogenix as part of plans to expand its reach into commercializing and developing treatments for rare diseases.
The new pancreatic cancer vaccine from ImmunityBio shows very promising results. Here’s what you need to know about the vaccine and its result from the tests.
The company’s co-Founder, President and CEO Dr. P. Peter Ghoroghchian, took time to discuss the company and the financing round with BioSpace.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
Gilead Sciences reported that about $250 million of counterfeit versions of its HIV drugs, Biktarvy and Descovy, were sold to pharmacies over two years.